Posts

Agios second shot at sickle cell disease falls short

on

Roche Ends Work on Tominersen and Early-Stage Huntington's Asset After Decade of Trials

on

Definium Therapeutics Prices $700 Million Upsized Public Offering

on

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

on

Beam's Base Editor Advances to Pivotal Development on Back of Impressive AATD Data

on

mAbxience and HP Drive the Use of Artificial Intelligence in Biomanufacturing and Biosimilar Development

on

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

on

HHS Cancels $500 Million in BARDA-Funded mRNA Vaccine Contracts Amid Strategic Shift

on

ALTO-203 Misses Depression Endpoint but Shows Positive Biomarker and Cognitive Signals

on

FDA Reinstates Generic Drug Policy Group After April Firings

on

Sanofi Announces $20 Billion US Investment Over Five Years

on

Thermo Fisher jumps on the US investment bandwagon with $2B in additional spending

on

Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology

on

HHS Terminates Funding for GeoVax’s Next-Generation COVID-19 Vaccine: Impacts and Developments

on

Isomorphic Labs raises $600M to push AI-designed drugs into clinic

on

Beyond Black Box: How Data-Driven AI Is Transforming RNA Medicine Development

on

MacroGenics Discontinues Development of Vobra Duo ADC After Phase 2 Prostate Cancer Trial Results

on